skip to main content
10.1145/2506583.2512360acmconferencesArticle/Chapter ViewAbstractPublication PagesbcbConference Proceedingsconference-collections
tutorial

HPVdb: a Data Mining System for Knowledge Discovery in Human Papillomavirus with Applications in T cell Immunology and Vaccinology

Published: 22 September 2013 Publication History

Abstract

High-risk human papilloma viruses (HPV) are the causes of many cancers, including cervical, anal, vulvar, vaginal, penile and oropharyngeal. To facilitate diagnosis, prognosis, and characterization of these cancers, we constructed the Human Papillomavirus T cell Antigen Database (HPVdb). It contains 2865 curated antigen entries of antigenic proteins derived from 18 genotypes of high-risk HPV and 18 genotypes of low-risk HPV. HPVdb also catalogs 96 verified T cell epitopes and 45 verified HLA ligands. Primary amino acid sequences of HPV antigens were collected and annotated from UniProtKB. T cell epitopes and HLA ligands were collected from data mining of scientific literature. The data were subject to extensive quality control (redundancy elimination, error detection, and vocabulary consolidation). A set of computational tools for in-depth analysis, such as sequence comparison using BLAST search, multiple alignments of antigens, classification of HPV types based on cancer risk, and T cell epitope/HLA ligand visualization, have been integrated in HPVdb. Predicted Class I and Class II HLA binding peptides for 15 common HLA alleles are included in this database as putative targets. HPVdb is a specialized database that integrates curated data and information with tailored analysis tools to facilitate data mining to aid rational vaccine design by discovery of vaccine targets. To our best knowledge, HPVdb is a unique data source providing a comprehensive list of antigen peptides in HPV. It is available at http://cvc.dfci.harvard.edu/hpv/ and http://met-hilab.bu.edu/hpvdb/.

References

[1]
Altschul, S. F., Gish, W., Miller, W., Myers, E. W., Lipman, D. J. 1990. Basic local alignment search tool. J Mol Biol. 215(3), 403--10.
[2]
de Martel, C., Ferlay, J., Franceschi, S., Vignat, J., Bray, F., Forman, D., and Plummer, M. 2012. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Onco. 3(6), 607--15.
[3]
de Sanjose, S., Quint W. G., et al. 2010. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 11(11), 1048--56.
[4]
de Villiers, E. M. 2013. Cross-roads in the classification of papillomaviruses. Virology.
[5]
Forman, D., de Martel, C., Lacey, C. J., Soerjomataram, I., Lortet-Tieulent, J., Bruni, L., Vignat, J., Ferlay, J., Bray, F., Plummer, M., and Franceschi, S. 2012. Global burden of human papillomavirus and related diseases. Vaccine 30(Suppl 5), F12--23.
[6]
Frazer, I. H. 2004. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol. 4(1), 46--54.
[7]
Ganguly, N. and Parihar, S. P. 2009. Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. Journal of biosciences 34 (1), 113--123.
[8]
Hoof, I., Peters, B., Sidney, J., Pedersen, L. E., Sette, A., Lund, O., Buus, S., Nielsen, M. 2009. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics. 61(1), 1--13.
[9]
Katoh, K., Misawa, K., Kuma, K., Miyata, T. 2002. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res. 30(14), 3059--66.
[10]
Keam, S. J., Harper, D. M. 2008. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) {Cervarix}. Drugs.68(3), 359--72.
[11]
Keskin, D. B., Reinhold, B., Lee, S. Y., Zhang, G. L., Lank, S., O'Connor, D. H., Berkowitz, R. S., Brusic, V., Kim, S.J., and Reinherz, E. L. 2011. Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens. Front Immunol. 2, 75.
[12]
Lehtinen, M. and Dillner, J. 2013. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol. 10(7), 400--10.
[13]
Lin, H. H., Zhang, G. L., Tongchusak, S., Reinherz, E. L., Brusic, V. 2008. Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinformatics. 9(Suppl 12), S22.
[14]
Lin, H.H., Ray S., Tongchusak, S., Reinherz, E. L., Brusic, V. 2008. Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol. 9, 8--20.
[15]
Moscicki, A. B., Schiffman, M., Burchell, A., Albero, G., Giuliano, A. R., Goodman, M. T., Kjaer, S. K., Palefsky, J. 2012. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 30(Suppl 5), F24--33.
[16]
Nielsen, M., Justesen, S., Lund, O., Lundegaard, C., Buus, S. 2010. NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res. 6, 9.
[17]
Riemer, A. B., Keskin, D. B., Zhang, G. L., Handley, M., Anderson, K. S., Brusic, V., Reinhold, B., and Reinherz, E. L. 2010. A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers. J Biol Chem. 285(38), 29608--22.
[18]
Siddiqui, M. A., Perry, C.M. 2006. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs. 66(9):1263--71.
[19]
Stanley, M. 2006. Immune responses to human papillomavirus. Vaccine 24(Suppl 1), S16--22.
[20]
Stern, P. L., van der Burg, S. H., Hampson, I. N., Broker, T. R., Fiander, A., Lacey, C. J., Kitchener, H. C., Einstein, M. H. 2012. Therapy of human papillomavirus-related disease. Vaccine. 30(Suppl 5), F71--82.
[21]
UniProt Consortium. 2010. The Universal Protein Resource (UniProt) in 2010. Nucleic Acids Res. 38, D142--8.
[22]
Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X. Kummer, J. A., Shah, K. V., Snijders, P. J., Peto, J., Meijer, C. J., and Muñoz, N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189(1), 12--19.
[23]
Zhang, G. L., Olsen, L. R., Kudahl, U. J., Chitkushev, L. T., and Brusic, V. 2013. Streamlining the development of immunological knowledge bases. Methods Mol Biol. (in press).
[24]
zur Hausen, H. 2002. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer, 2(5), 342--350.

Cited By

View all
  • (2021)TANTIGEN 2.0: a knowledge base of tumor T cell antigens and epitopesBMC Bioinformatics10.1186/s12859-021-03962-722:S8Online publication date: 14-Apr-2021

Index Terms

  1. HPVdb: a Data Mining System for Knowledge Discovery in Human Papillomavirus with Applications in T cell Immunology and Vaccinology

      Recommendations

      Comments

      Information & Contributors

      Information

      Published In

      cover image ACM Conferences
      BCB'13: Proceedings of the International Conference on Bioinformatics, Computational Biology and Biomedical Informatics
      September 2013
      987 pages
      ISBN:9781450324342
      DOI:10.1145/2506583
      Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than ACM must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from [email protected]

      Sponsors

      Publisher

      Association for Computing Machinery

      New York, NY, United States

      Publication History

      Published: 22 September 2013

      Permissions

      Request permissions for this article.

      Check for updates

      Author Tags

      1. Human papilloma viruses
      2. Immunological databases
      3. T cell epitopes
      4. vaccine target discovery
      5. viral antigens

      Qualifiers

      • Tutorial
      • Research
      • Refereed limited

      Conference

      BCB'13
      Sponsor:
      BCB'13: ACM-BCB2013
      September 22 - 25, 2013
      Wshington DC, USA

      Acceptance Rates

      BCB'13 Paper Acceptance Rate 43 of 148 submissions, 29%;
      Overall Acceptance Rate 254 of 885 submissions, 29%

      Contributors

      Other Metrics

      Bibliometrics & Citations

      Bibliometrics

      Article Metrics

      • Downloads (Last 12 months)1
      • Downloads (Last 6 weeks)0
      Reflects downloads up to 20 Feb 2025

      Other Metrics

      Citations

      Cited By

      View all
      • (2021)TANTIGEN 2.0: a knowledge base of tumor T cell antigens and epitopesBMC Bioinformatics10.1186/s12859-021-03962-722:S8Online publication date: 14-Apr-2021

      View Options

      Login options

      View options

      PDF

      View or Download as a PDF file.

      PDF

      eReader

      View online with eReader.

      eReader

      Figures

      Tables

      Media

      Share

      Share

      Share this Publication link

      Share on social media